BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35355122)

  • 1. Contrast-enhanced ultrasonography for blood flow detection in hepatocellular carcinoma during lenvatinib therapy.
    Matsumoto N; Ogawa M; Kaneko M; Arima S; Kumagawa M; Watanabe Y; Hirayama M; Masuzaki R; Kanda T; Moriyama M
    J Med Ultrason (2001); 2022 Jul; 49(3):425-432. PubMed ID: 35355122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.
    Cho YZ; Park SY; Choi EH; Baik SK; Kwon SO; Kim YJ; Cha SH; Kim MY
    Clin Mol Hepatol; 2015 Jun; 21(2):165-74. PubMed ID: 26157754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
    World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results.
    Ross CJ; Rennert J; Schacherer D; Girlich C; Hoffstetter P; Heiss P; Jung W; Feuerbach S; Zorger N; Jung EM
    Clin Hemorheol Microcirc; 2010; 46(2-3):101-15. PubMed ID: 21135486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-Enhanced Ultrasound to Monitor Early Recurrence of Primary Hepatocellular Carcinoma after Curative Treatment.
    Liu LF; Ding ZL; Zhong JH; Li HX; Liu JJ; Li H; Li LQ
    Biomed Res Int; 2018; 2018():8910562. PubMed ID: 30533441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
    Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 9. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
    Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
    Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
    Kamachi N; Nakano M; Okamura S; Niizeki T; Iwamoto H; Shimose S; Shirono T; Noda Y; Kuromatsu R; Koga H; Torimura T
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1471. PubMed ID: 34105904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography.
    Paul SB; Dhamija E; Gamanagatti SR; Sreenivas V; Yadav DP; Jain S; Shalimar ; Acharya SK
    Diagn Interv Imaging; 2017 Mar; 98(3):253-260. PubMed ID: 27692674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients.
    Schwarze V; Marschner C; Völckers W; de Figueiredo GN; Rübenthaler J; Clevert DA
    Clin Hemorheol Microcirc; 2020; 76(2):155-160. PubMed ID: 32925017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience.
    Catalano O; Izzo F; Vallone P; Sandomenico F; Albino V; Nunziata A; Fusco R; Petrillo A
    Acta Radiol; 2015 Feb; 56(2):133-42. PubMed ID: 24523360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
    Kaufmann S; Schulze M; Spira D; Horger M
    Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis.
    Zhong J; Su Z; Zhang Y; Zhang H; Lin P; Tang X; Zheng R
    J Ultrasound Med; 2018 Aug; 37(8):1881-1890. PubMed ID: 29380404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.
    Lu MD; Yu XL; Li AH; Jiang TA; Chen MH; Zhao BZ; Zhou XD; Wang JR
    Ultrasound Med Biol; 2007 Nov; 33(11):1736-49. PubMed ID: 17629608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma.
    Kono Y; Lucidarme O; Choi SH; Rose SC; Hassanein TI; Alpert E; Mattrey RF
    J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):57-65. PubMed ID: 17296705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment.
    Zhang XY; Luo Y; Wen TF; Jiang L; Li C; Zhong XF; Zhang JY; Ling WW; Yan LN; Zeng Y; Wu H
    World J Gastroenterol; 2014 Sep; 20(35):12628-36. PubMed ID: 25253968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS).
    Moschouris H; Kalokairinou-Motogna M; Vrakas S; Papadatou A; Karagiannis E; Kiltenis M; Kladis-Kalentzis K; Marmaridou K; Papadogeorgopoulos N; Malagari K
    Med Ultrason; 2017 Apr; 19(2):134-142. PubMed ID: 28440346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial contrast-enhanced ultrasound (IA CEUS) for localization of hepatocellular carcinoma (HCC) supply during transarterial chemoembolization (TACE): a case series.
    Lekht I; Nayyar M; Luu B; Guichet PL; Ho J; Ter-Oganesyan R; Katz M; Gulati M
    Abdom Radiol (NY); 2017 May; 42(5):1400-1407. PubMed ID: 28008454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.